2016 Concordia Summit: The Future of Immunotherapy

Share this content:
Speakers at the 2016 Concordia Summit’s panel, “Precision Medicine in Cancer Research,” discussed the importance and future of immunotherapy for cancer treatment.
Speakers at the 2016 Concordia Summit’s panel, “Precision Medicine in Cancer Research,” discussed the importance and future of immunotherapy for cancer treatment.

Speakers at the 2016 Concordia Summit's panel, “Precision Medicine in Cancer Research,” discussed the importance and future of immunotherapy for cancer treatment.1

Dr James R. Downing, president and chief executive officer of St Jude Children's Research Hospital in Memphis, Tennessee, noted the vastly improved survival rates among pediatric patients with cancer, particularly acute lymphoblastic leukemia (ALL).

Other panel members included Dr Stephen Nimer, director of the Sylvester Comprehensive Cancer Center in Miami, Florida, and Dr Jedd Wolchok, chief of the melanoma and immunotherapeutics service at the Memorial Sloan Kettering Cancer Center in New York, New York.

The panel agreed that future success in cancer therapy will depend not only on the invention of new drugs, but on the ability of oncologists and researchers to more accurately target specific cancers, using combinations of the drugs we already have.

Promising future therapeutic combinations, according to panel members, include epigenetic therapies, which can influence cancer cell phenotypes, and immunotherapies that target “genetically damaged” tumors.

One difficulty is the complexity and financial burden of sequencing tumors, particularly those of a heterogenetic variety. In precision treatment, variety “exists at all levels,” including the individual, the cancer, the cellular, and the genetic.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters